These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20430742)

  • 1. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy.
    Naumnik W; Nilklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(4):703-9. PubMed ID: 20430742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
    Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
    Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
    Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
    Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy.
    Naumnik W; Niklińska W; Ossolińska M; Chyczewska E
    Folia Histochem Cytobiol; 2009; 47(2):207-13. PubMed ID: 19995705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery.
    Tang XP; Li J; Yu LC; Chen YC; Shi SB; Zhu LR; Chen P
    Lung Cancer; 2013 Aug; 81(2):273-9. PubMed ID: 23756092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
    Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
    Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer.
    Shang GH; Jia CQ; Tian H; Xiao W; Li Y; Wang AH; Dong L; Lin DJ
    Respir Med; 2009 Dec; 103(12):1949-53. PubMed ID: 19535236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
    Dudek AZ; Mahaseth H
    Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients.
    Chen P; Li J; Ge LP; Dai CH; Li XQ
    Respirology; 2010 Apr; 15(3):501-9. PubMed ID: 20210890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of serum Tie-2 and vascular endothelial growth factor levels in cancer patients.
    Seker MM; Sancaktar E; Acibucu DO; Filiz AK; Deveci K; Bahceci A; Kacan T; Babacan N; Yuce S
    Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2929-32. PubMed ID: 24254563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of microwave ablation or its combination with whole-body chemotherapy on serum vascular endothelial growth factor levels in patients with stage IIIB/IV NSCLC.
    Sun YH; Song PY; Guo Y; Pang M; He WN; Zhang WH; Sheng LJ
    Genet Mol Res; 2015 Aug; 14(3):10015-25. PubMed ID: 26345938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
    Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
    Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
    Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
    Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
    Hu Y; Hu MM; Shi GL; Han Y; Li BL
    Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivin antiapoptotic gene expression as a prognostic factor in non-small cell lung cancer: in situ hybridization study.
    Karczmarek-Borowska B; Filip A; Wojcierowski J; Smoleń A; Pilecka I; Jabłonka A
    Folia Histochem Cytobiol; 2005; 43(4):237-42. PubMed ID: 16382892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.